(Q37771531)

22 August 2017

1 reference

title

Clinical recommendations for the use of everolimus in heart transplantation (English)

1 reference

22 August 2017

0 references

Nicolás Manito

1

1 reference

22 August 2017

Juan F Delgado

2

1 reference

22 August 2017

Maria G Crespo-Leiro

3

1 reference

22 August 2017

Francisco González-Vílchez

4

1 reference

22 August 2017

Luis Almenar

5

1 reference

22 August 2017

José M Arizón

6

1 reference

22 August 2017

Beatriz Díaz

7

1 reference

22 August 2017

Juan Fernández-Yáñez

8

1 reference

22 August 2017

Sònia Mirabet

9

1 reference

22 August 2017

Jesús Palomo

10

1 reference

22 August 2017

José L Rodríguez Lambert

11

1 reference

22 August 2017

Eulàlia Roig

12

1 reference

22 August 2017

Javier Segovia

13

1 reference

22 August 2017

publication date

1 July 2010

1 reference

22 August 2017

published in

Transplantation Reviews

1 reference

22 August 2017

volume

24

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

129-142

1 reference

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Malignancy after heart transplantation: incidence, prognosis and risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report--2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Immunosuppressive drugs and the risk of cancer after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Chromosome aberrations in human cells following treatment with imuran. Preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Azathioprine and UVA light generate mutagenic oxidative DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Nonmelanoma skin cancer after liver transplantation. Study of risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Rescue therapy: a role for sirolimus in lung and heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus improves renal function in cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Preservation of renal function after heart transplantation: initial single-center experience with sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus conversion for patients with posttransplant Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus-induced remission of posttransplantation lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus in clinical practice--renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Simvastatin initiated early after heart transplantation: 8-year prospective experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Ezetimibe in heart transplantation: initial experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Reversible sirolimus-associated pneumonitis after heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus-associated interstitial pneumonitis in a patient with a heart transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus-associated pneumonitis in 3 heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Pharmacokinetic interaction between verapamil and everolimus in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Blood concentrations of everolimus are markedly increased by ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Effect of multiple-dose erythromycin on everolimus pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Everolimus drug interactions: application of a classification system for clinical decision making

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

Chronic anemia in heart transplant patients: prevalence, predisposing factors and prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.005

10.1016/J.TRRE.2010.01.005

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference